1. Home
  2. AERT vs AKTX Comparison

AERT vs AKTX Comparison

Compare AERT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AERT
  • AKTX
  • Stock Information
  • Founded
  • AERT 2012
  • AKTX N/A
  • Country
  • AERT Singapore
  • AKTX United States
  • Employees
  • AERT N/A
  • AKTX N/A
  • Industry
  • AERT Professional Services
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AERT Consumer Discretionary
  • AKTX Health Care
  • Exchange
  • AERT Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • AERT 38.3M
  • AKTX 37.2M
  • IPO Year
  • AERT N/A
  • AKTX N/A
  • Fundamental
  • Price
  • AERT $1.07
  • AKTX $1.14
  • Analyst Decision
  • AERT
  • AKTX
  • Analyst Count
  • AERT 0
  • AKTX 0
  • Target Price
  • AERT N/A
  • AKTX N/A
  • AVG Volume (30 Days)
  • AERT 228.9K
  • AKTX 26.9K
  • Earning Date
  • AERT 08-14-2025
  • AKTX 08-18-2025
  • Dividend Yield
  • AERT N/A
  • AKTX N/A
  • EPS Growth
  • AERT N/A
  • AKTX N/A
  • EPS
  • AERT N/A
  • AKTX N/A
  • Revenue
  • AERT $70,198,000.00
  • AKTX N/A
  • Revenue This Year
  • AERT N/A
  • AKTX N/A
  • Revenue Next Year
  • AERT N/A
  • AKTX N/A
  • P/E Ratio
  • AERT N/A
  • AKTX N/A
  • Revenue Growth
  • AERT N/A
  • AKTX N/A
  • 52 Week Low
  • AERT $0.46
  • AKTX $0.85
  • 52 Week High
  • AERT $2.93
  • AKTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • AERT 56.97
  • AKTX 43.82
  • Support Level
  • AERT $1.03
  • AKTX $1.10
  • Resistance Level
  • AERT $1.32
  • AKTX $1.18
  • Average True Range (ATR)
  • AERT 0.18
  • AKTX 0.05
  • MACD
  • AERT -0.02
  • AKTX 0.00
  • Stochastic Oscillator
  • AERT 31.33
  • AKTX 39.52

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: